Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers

Malignant glioma, the most frequent and aggressive central nervous system (CNS) tumor, severely threatens human health. One reason, for its poor prognosis and short survival is the presence of the blood-brain barrier (BBB) and blood-brain tumor battier (BBTB), which restrict the penetration of therapeutics into the brain at different stages of glioma. Herein, inspired by the peptide stapling,technique, we designed a cyclic RGD ligand via an all-hydrocarbon staple (stapled RGD, sRGD) to facilitate BBB penetration while retaining the capacity. Of BBTB penetration and targeting ability to glioma cells. As expected, sRGD-modified micelles were able to penetrate the in Vitro BBB model while retaining the glioma targeted capability. The results of the in vivo imaging studies further revealed that this nanocarrier could not only efficientlytransverse the intact BBB of normal mice, but also could specifically target glioma cells of intracranial glioma-bearing nude mice. Furthermore, Paclitaxel-loaded sRGD-modified micelles exhibited improved antiglioma efficacy in vitro and significantly prolonged survival time of glioma-bearing nude mice. Overall, this sRGD peptide showed potency for glioma-targeted drug delivery by overcoming multiple barriers.